Some powerful new cancer drugs trigger diabetes for unknown reasons

shutterstock cancer treatment x

The first two rounds of treatment went off without a hitch. But last November, after receiving a third dose of potent immunotherapy for his skin cancer, Rich Lenihan started to feel tired and weak.

He was urinating constantly, and no amount of water could abate his thirst. A blood test revealed glucose levels that were through the roof.

Lenihan, at age 62, had developed a disease akin to type 1 diabetes — formerly called “juvenile” diabetes — a rare complication of drugs known as checkpoint inhibitors that rev up the body’s immune assault on tumor tissue.

Roughly 1% of patients receiving immunotherapy drugs experience the same irreversible side effect. Making matters worse, oncologists have little clue why.

Related article:  Podcast: 'Clean' wine isn't so clean; FDA blocks hemophilia gene therapy; Universal flu vaccine?

On [May 29], the Parker Institute for Cancer Immunotherapy, JDRF (formerly called the Juvenile Diabetes Research Foundation), and the Helmsley Charitable Trust announced they are joining forces to launch a $10 million, three-year research initiative designed to identify the root causes of drug-induced diabetes among cancer patients.

Eventually, researchers involved in the project hope to discover new therapeutic strategies for preventing diabetic complications without sacrificing any of the cancer-destroying potential of livesaving immunotherapy drugs.

Read full, original post: A lifesaver with a catch: Powerful new cancer drugs can trigger diabetes — and no one is certain why

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend